New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:37 EDTALXNAlexion granted ODD to Soliris by FDA
Alexion Pharmaceuticals announced that the FDA has granted an orphan drug designation, or ODD, to Soliris, a first-in-class terminal complement inhibitor, for the prevention of delayed graft function, or DGF in renal transplant patients. DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
06:31 EDTALXNAlexion announces $500M share repurchase program
Alexion Pharmaceuticals announced that the company’s board has authorized a new share repurchase program of up to $500M. The new share repurchase program will take effect upon completion of the company’s current program, which has approximately $22M remaining of its previously authorized $400M.
December 12, 2014
08:01 EDTALXNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 10, 2014
16:20 EDTALXNAlexion reports Soliris granted orphan drug designation in Japan
Subscribe for More Information
December 9, 2014
05:33 EDTALXNAlexion presents Soliris data at ASH
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use